{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T07:46:33Z","timestamp":1777535193755,"version":"3.51.4"},"reference-count":27,"publisher":"American Academy of Pediatrics (AAP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,4,1]]},"DOI":"10.1542\/peds.2016-0057","type":"journal-article","created":{"date-parts":[[2016,3,17]],"date-time":"2016-03-17T12:28:50Z","timestamp":1458217730000},"source":"Crossref","is-referenced-by-count":35,"title":["Concerns for Development After Bevacizumab Treatment of ROP"],"prefix":"10.1542","volume":"137","author":[{"given":"Graham E.","family":"Quinn","sequence":"first","affiliation":[{"name":"Division of Ophthalmology, The Children\u2019s Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian A.","family":"Darlow","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, University of Otago, Christchurch, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2016,4,1]]},"reference":[{"issue":"12","key":"2021120919101585100_B1","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","article-title":"Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial.","volume":"121","author":"Early Treatment for Retinopathy of Prematurity Cooperative Group","year":"2003","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"2021120919101585100_B2","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1001\/archophthalmol.2010.72","article-title":"Final visual acuity results in the early treatment for retinopathy of prematurity study.","volume":"128","author":"Good","year":"2010","journal-title":"Arch Ophthalmol"},{"issue":"11","key":"2021120919101585100_B3","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/S0161-6420(91)32074-8","article-title":"Incidence and early course of retinopathy of prematurity.","volume":"98","author":"Palmer","year":"1991","journal-title":"Ophthalmology"},{"issue":"3","key":"2021120919101585100_B4","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1001\/archopht.123.3.311","article-title":"15-Year outcomes following threshold retinopathy of prematurity: final results from the multicenter trial of cryotherapy for retinopathy of prematurity.","volume":"123","author":"Palmer","year":"2005","journal-title":"Arch Ophthalmol"},{"issue":"12","key":"2021120919101585100_B5","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1001\/archopht.121.12.1697","article-title":"Risk analysis of prethreshold retinopathy of prematurity.","volume":"121","author":"Hardy","year":"2003","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"2021120919101585100_B6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1542\/peds.2004-1413","article-title":"The incidence and course of retinopathy of prematurity: findings from the early treatment for retinopathy of prematurity study.","volume":"116","author":"Good","year":"2005","journal-title":"Pediatrics"},{"issue":"5","key":"2021120919101585100_B7","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1001\/archopht.120.5.595","article-title":"Multicenter trial of cryotherapy for retinopathy of prematurity: natural history ROP: ocular outcome at 5(1\/2) years in premature infants with birth weights less than 1251 g.","volume":"120","author":"Cryotherapy for Retinopathy of Prematurity Cooperative Group","year":"2002","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"2021120919101585100_B8","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1542\/peds.2011-3028","article-title":"Mortality and neonatal morbidity among infants 501 to 1500 grams from 2000 to 2009.","volume":"129","author":"Horbar","year":"2012","journal-title":"Pediatrics"},{"issue":"7","key":"2021120919101585100_B9","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity.","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"2021120919101585100_B10","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jaapos.2009.12.002","article-title":"Avastin as monotherapy for retinopathy of prematurity.","volume":"14","author":"Mintz-Hittner","year":"2010","journal-title":"J AAPOS"},{"issue":"3","key":"2021120919101585100_B11","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10384-014-0310-z","article-title":"Intravitreal injection of bevacizumab for retinopathy of prematurity.","volume":"58","author":"Kuniyoshi","year":"2014","journal-title":"Jpn J Ophthalmol"},{"issue":"11","key":"2021120919101585100_B12","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1136\/bjo.2008.140657","article-title":"Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study.","volume":"92","author":"Kusaka","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"2021120919101585100_B13","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1097\/IAE.0b013e318159ec6b","article-title":"Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity.","volume":"28","author":"Quiroz-Mercado","year":"2008","journal-title":"Retina"},{"issue":"11","key":"2021120919101585100_B14","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","article-title":"Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial.","volume":"132","author":"Geloneck","year":"2014","journal-title":"JAMA Ophthalmol"},{"issue":"8","key":"2021120919101585100_B15","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/archophthalmol.2012.592","article-title":"Reactivation of retinopathy of prematurity after bevacizumab injection.","volume":"130","author":"Hu","year":"2012","journal-title":"Arch Ophthalmol"},{"issue":"7","key":"2021120919101585100_B16","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s00417-008-0786-7","article-title":"Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity.","volume":"246","author":"Honda","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"2021120919101585100_B17","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/eye.2009.156","article-title":"Paradoxical vascular-fibrotic reaction after intravitreal bevacizumab for retinopathy of prematurity [published correction appears in Eye (Lond). 2010;24(1):202].","volume":"24","author":"Zepeda-Romero","year":"2010","journal-title":"Eye (Lond)"},{"issue":"11","key":"2021120919101585100_B18","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.ophtha.2014.05.015","article-title":"Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings.","volume":"121","author":"Lepore","year":"2014","journal-title":"Ophthalmology"},{"issue":"2","key":"2021120919101585100_B19","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/IAE.0b013e318275394a","article-title":"Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5 years of follow-up.","volume":"33","author":"Mart\u00ednez-Castellanos","year":"2013","journal-title":"Retina"},{"key":"2021120919101585100_B20","author":"Sato","year":"2012"},{"key":"2021120919101585100_B21","article-title":"Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity.","author":"Luu","journal-title":"Pediatrics"},{"issue":"3","key":"2021120919101585100_B22","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1542\/peds.2004-1238","article-title":"Impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk for chronic lung disease.","volume":"115","author":"Doyle","year":"2005","journal-title":"Pediatrics"},{"issue":"3","key":"2021120919101585100_B23","doi-asserted-by":"crossref","first-page":"F177","DOI":"10.1136\/fn.83.3.F177","article-title":"Early postnatal dexamethasone treatment and increased incidence of cerebral palsy.","volume":"83","author":"Shinwell","year":"2000","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"6","key":"2021120919101585100_B24","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.jpeds.2014.07.049","article-title":"An update on the impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk of bronchopulmonary dysplasia.","volume":"165","author":"Doyle","year":"2014","journal-title":"J Pediatr"},{"key":"2021120919101585100_B25","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/pr.2013.205","article-title":"Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010.","volume":"74","author":"Blencowe","year":"2013","journal-title":"Pediatr Res"},{"issue":"5","key":"2021120919101585100_B26","doi-asserted-by":"crossref","first-page":"e518","DOI":"10.1542\/peds.2004-1180","article-title":"Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate, and high levels of development: implications for screening programs.","volume":"115","author":"Gilbert","year":"2005","journal-title":"Pediatrics"},{"issue":"2","key":"2021120919101585100_B27","doi-asserted-by":"crossref","first-page":"F170","DOI":"10.1136\/archdischild-2011-301148","article-title":"Are we there yet? Bevacizumab therapy for retinopathy of prematurity.","volume":"98","author":"Darlow","year":"2013","journal-title":"Arch Dis Child Fetal Neonatal Ed"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2016-0057\/1095650\/peds_20160057.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2016-0057\/1095650\/peds_20160057.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T05:30:13Z","timestamp":1639114213000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/137\/4\/e20160057\/81377\/Concerns-for-Development-After-Bevacizumab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,1]]},"references-count":27,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2016,4,1]]},"published-print":{"date-parts":[[2016,4,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2016-0057","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,1]]},"article-number":"e20160057"}}